白细胞介素-34改善多微生物脓毒症小鼠的生存与细菌清除
该研究为前瞻性随机动物实验与体外研究,在盲肠结扎穿刺诱导的多微生物脓毒症小鼠模型中评估白细胞介素-34的作用。结果显示,脓毒症患者和小鼠模型中白细胞介素-34水平均显著升高;给予白细胞介素-34可改善生存和细菌清除,抑制血管渗漏和器官损伤;中和白细胞介素-34则增加死亡率并降低细菌清除。机制上,白细胞介素-34促进感染部位中性粒细胞和巨噬细胞浸润,并升高腹腔趋化因子配体1和2水平;耗竭中性粒细胞或巨噬细胞可逆转其保护作用。作者首次报道白细胞介素-34在脓毒症中的潜在治疗作用,并认为其是开发脓毒症治疗药物的新靶点。
要点
- 在盲肠结扎穿刺诱导的多微生物脓毒症小鼠中,给予白细胞介素-34可改善生存和细菌清除。
- 白细胞介素-34可抑制盲肠结扎穿刺后多微生物脓毒症的血管渗漏和器官损伤。
- 中和白细胞介素-34可增加脓毒症小鼠死亡率并降低细菌清除。
- 白细胞介素-34的保护作用依赖中性粒细胞和巨噬细胞:耗竭其中任一种均可逆转其保护作用。
- 脓毒症患者和盲肠结扎穿刺小鼠模型中白细胞介素-34水平均显著升高。
适用人群与场景
- 体内研究使用野生型C57BL/6小鼠,采用盲肠结扎穿刺诱导多微生物脓毒症模型。
- 体外研究使用脓毒症患者和健康人的血液样本。
研究设计与关键结果
- 研究类型为前瞻性随机动物实验与体外研究,研究地点为大学医院研究实验室。
- 白细胞介素-34在人类脓毒症和盲肠结扎穿刺诱导的实验性脓毒症中均显著升高。
- 给予白细胞介素-34可改善盲肠结扎穿刺诱导多微生物脓毒症后的生存和细菌清除,并抑制血管渗漏和器官损伤。
- 中和白细胞介素-34可增加脓毒症小鼠死亡率并降低细菌清除。
- 白细胞介素-34处理小鼠感染部位中性粒细胞和巨噬细胞浸润增加,腹腔内中性粒细胞趋化因子(C-X-C基序)配体1和巨噬细胞趋化因子C-C基序配体2产生升高。
- 耗竭中性粒细胞或巨噬细胞可逆转白细胞介素-34介导的多微生物脓毒症保护作用。
证据类型、等级与局限
- 证据类型为前瞻性随机动物实验与体外研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者首次报道白细胞介素-34在脓毒症中的潜在治疗作用,并认为白细胞介素-34是开发脓毒症治疗药物的新靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Sepsis is a devastating condition with a high mortality rate and limited treatments. Sepsis is characterized by a failed host immune response to contain the infection, resulting in organ dysfunction. Interleukin-34 is new cytokine involved in infection and immunity. Whether interleukin-34 is beneficial or deleterious to sepsis and the underlying mechanisms remains unknown.
DESIGN: Prospective randomized animal investigation and in vitro studies.
SETTING: Research laboratory at a university hospital.
SUBJECTS: Wild-type C57BL/6 mice were used for in vivo studies, and septic human patients and healthy human subjects were used to obtain blood for in vitro studies.
INTERVENTIONS: Interleukin-34 concentrations were measured in human sepsis patients and healthy individuals. The effects of interleukin-34 administration on survival, bacterial burden, organ injury, and inflammatory response were assessed in a murine model of cecal ligation and puncture-induced polymicrobial sepsis.
MEASUREMENTS AND MAIN RESULTS: Interleukin-34 levels were significantly elevated in human sepsis and cecal ligation and puncture-induced experimental sepsis. Interleukin-34 administration improved survival and bacterial clearance, although suppressed vascular leakage and organ injury after cecal ligation and puncture-induced polymicrobial sepsis. Neutralization of interleukin-34 increased mortality rate and decreased bacterial clearance in septic mice. An increased neutrophil and macrophage influx were developed in interleukin-34-treated mice at the site of infection, accompanied by elevated production of neutrophil chemokine chemokine (C-X-C motif) ligand 1 and macrophage chemokine C-C motif chemokine ligand 2 in the peritoneal cavity. Depletion of neutrophils or macrophages reversed interleukin-34-mediated protection against polymicrobial sepsis.
CONCLUSIONS: We reported for the first time a potential therapeutic role for interleukin-34 in sepsis and suggested that interleukin-34 is a novel target for the development of therapeutic agents against sepsis.
参考来源
- Lin X, Luo H, Yan X, et al. Interleukin-34 Ameliorates Survival and Bacterial Clearance in Polymicrobial Sepsis. Crit Care Med. 2018. PMID: 29384785. doi:10.1097/CCM.0000000000003017
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。